| Identification | Back Directory | [Name]
RWJ 50271 | [CAS]
162112-37-0 | [Synonyms]
RWJ 50271
N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide
N-(3-Hydroxypropyl)-5-methyl-1-[-4-[3-(trifluoromethyl)phenyl)]-2-thiazolyl]-1H-pyrazole-4-carboxamide
1H-Pyrazole-4-carboxamide, N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-2-thiazolyl]- | [Molecular Formula]
C18H17F3N4O2S | [MDL Number]
MFCD00938572 | [MOL File]
162112-37-0.mol | [Molecular Weight]
410.41 |
| Chemical Properties | Back Directory | [density ]
1.44±0.1 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
<41.04mg/ml in DMSO | [form ]
Solid | [pka]
14.28±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
RWJ 50271 is an inhibitor of LFA-1/ICAM-1 mediated cell adhesion. | [in vivo]
RWJ 50271 (50 mg/kg; p.o.) is effective in animal model of inflammation[1].
| Animal Model: | Mice, the delayed-type hypersensitivity [DTH] reaction model[1] | | Dosage: | 50 mg/kg | | Administration: | Oral administration | | Result: | Significantly reduced foot pad swelling (>50%) 48 h after the challenge. |
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|